CLL Extended 2: FCM CLL Panel and Karyotyping and FISH For 17p and ATM Del

If you have been diagnosed with CLL, this test provides essential information about the genetic makeup of the leukemia cells. This information can influence prognosis, treatment options, and management strategies.

No specific preparation is required. However, it's important to inform your doctor of any medications or supplements you are taking as they may interfere with the test results.

This test provides detailed information about the properties and genetic characteristics of the CLL cells, including chromosomal abnormalities like the 17p deletion and ATM deletion.

The detection of chromosomal abnormalities, especially 17p and ATM deletions, may suggest that the disease could be more aggressive or resistant to certain treatments. This information helps doctors in devising an effective treatment plan.

In a normal sample, the 17p and ATM deletions should not be present. Their presence in CLL cells is indicative of chromosomal abnormalities.

If the results of this test are abnormal, it is important to consult a hematologist or an oncologist who specializes in the treatment of blood cancers.

The levels detected in this test can be affected by the progression of CLL, previous treatments, and the presence of other chromosomal abnormalities.

Chromosomal abnormalities in CLL are not preventable as they are genetic in nature. However, early detection and appropriate management can sometimes slow the progression of the disease.

As of now, CLL is usually not curable, but it can often be managed effectively for many years with the appropriate treatment.

Newer targeted therapies such as ibrutinib and venetoclax are showing promising results in treating CLL patients with 17p and ATM deletions.

The frequency of this test should be determined by your doctor, based on the progression of the disease and the treatment plan.

While this test can provide information on the genetic makeup of the CLL cells, which is useful for prognosis, it cannot predict with certainty how the disease will progress in every individual.

Yes, it is possible for these deletions to develop as the disease progresses, which is why repeated testing may sometimes be necessary.

Understanding the genetic composition of CLL cells is critical for managing the disease effectively. The CLL Extended 2 test, which analyzes cell properties through Flow Cytometry and detects chromosomal abnormalities through Karyotyping and FISH, provides essential information that can help your doctor devise a more personalized and effective treatment plan. Especially with chromosomal abnormalities like 17p and ATM deletions, knowing what you're up against can lead to better outcomes through targeted therapies. Regular monitoring and strict adherence to your doctor's recommendations are crucial in managing CLL.